生物直角键裂解化学在需要时激活产物药物:机会和挑战
1Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, College of Pharmaceutical Science, Soochow University, Suzhou 215123, China.
Journal of medicinal chemistry
|December 12, 2023
概括
生物对等前体药物通过控制药物释放来提供精确的癌症治疗. 最近的进展显示出有前途,一个前药进入临床试验,突出了这一创新的治疗策略.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 传统的前药物策略缺乏有效治疗癌症所需的精确时间和空间控制.
- 生物对角化学为高特异性的前药激活提供了一种新的方法.
研究的目的:
- 审查最近 (2019-2023) 癌症治疗中的生物对等前药物策略的进展.
- 批判性地评估这些新兴技术的优缺点.
- 确定该领域的未来挑战和研究方向.
主要方法:
- 2019-2023年科学出版物的文献综述,重点关注生物对等前药物.
- 对生物对等前药物临床试验进展的分析.
- 批判性讨论不同生物对等激活化学的优缺点.
主要成果:
- 在生物对等前药物开发方面取得了重大进展,使药物能够精确激活.
- 一种生物对等原药已经进入第二阶段临床试验.
- 在时空药物递送和克服个体异质性方面有明显的优势.
结论:
- 生物直角前药物代表了针对性癌症治疗的重大飞跃.
- 需要进一步的研究来解决剩余的挑战,并优化临床翻译.
- 该领域在改善癌症治疗结果方面具有重大前景.
相关概念视频
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Principles of Drug Action
6.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K


